

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

(51) International Patent Classification 6 : A61K 9/16, 9/50		A1	(11) International Publication Number: WO 96/12473 (43) International Publication Date: 2 May 1996 (02.05.96)
(21) International Application Number: PCT/US95/13527 (22) International Filing Date: 16 October 1995 (16.10.95) (30) Priority Data: 335,148 25 October 1994 (25.10.94) US (60) Parent Application or Grant (63) Related by Continuation US Not furnished (CON) Filed on Not furnished		(74) Agents: ROBINSON, Joseph, R. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022 (US). (81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(71) Applicant (for all designated States except US): EMISPHERE TECHNOLOGIES, INC. [US/US]; 15 Skyline Drive, Hawthorne, NY 10532 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): LEONE-BAY, Andrea [US/US]; 20 Woodland Way, Ridgefield, CT 06877 (US). PATON, Duncan, R. [GB/US]; 323 Nash Road, Purdys, NY 10578 (US). HO, Kok-Kan [MK/US]; 70 Barker Street, Mount Kisco, NY 10549 (US). DeMORIN, Frenel [HT/US]; 42 Prospect Street, Spring Valley, NY 10977 (US).			

57) Abstract

Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

10

COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS

FIELD OF THE INVENTION

The present invention relates to compounds for delivering active
15 agents, and particularly biologically active agents such as, for example,
bioactive peptides and the like. These compounds are used as carriers to
facilitate the delivery of a cargo to a target. The carriers are modified amino
acids and are well suited to form non-covalent mixtures with biologically-active
agents for oral administration to animals. Methods for the preparation and for
20 the administration of such compositions are also disclosed.

BACKGROUND OF THE INVENTION

Conventional means for delivering active agents are often severely
limited by biological, chemical, and physical barriers. Typically, these barriers
25 are imposed by the environment through which delivery occurs, the environment
of the target for delivery, or the target itself.

Biologically active agents are particularly vulnerable to such
barriers. For example in the delivery to animals of pharmacological and
therapeutic agents, barriers are imposed by the body. Examples of physical
30 barriers are the skin and various organ membranes that must be traversed before
reaching a target. Chemical barriers include, but are not limited to, pH
variations, lipid bi-layers, and degrading enzymes.

These barriers are of particular significance in the design of oral
delivery systems. Oral delivery of many biologically active agents would be the

route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal (GI) tract, powerful digestive enzymes, and active agent impermeable gastro-intestinal membranes. Among the numerous agents which are not typically amenable to oral
5 administration are biologically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, or the like.

10 Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g.,
15 pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.

Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel et al. (1976), *FEBS Letters*, Vol. 62, pg. 60; and Hashimoto et al. (1979),
20 *Endocrinology Japan*, Vol. 26, pg. 337.

However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the
25 systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.


More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example,
30 U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.

There is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents.

5 SUMMARY OF THE INVENTION


Compounds useful in the delivery of active agents are provided. These compounds include

10




I

15




II

20




III

25



IV


30



V


4

5




VI

10




VII

15




VIII

20




IX

25




X

30




XI

5




XII

10




XIII

15




XIV

20




XV

25



XVI


30



XVII


6

5




XVIII

10




XIX

15




XX

20




XXI

25




XXII

30




XXIII

5




XXIV

10




XXV

15




XXVI

20




XXVII

25



XXVIII


30



XXIX


8

5




XXX

10




XXXI

15




XXXII

20




XXXIII

25




XXXIV

30




XXXV

5




XXXVI

10




XXXVII

15



XXXVIII


20



XXXIX


25

30




XL

5




XLI -

10




XLII

15



XLIII


20



25

XLIV

30



XLV

35

or salts thereof.

Compositions comprising at least one biologically active-agent and at least one of the compounds above are also provided. Further contemplated by the present invention are dosage unit forms that include these compositions.

Also contemplated is a method for preparing these compositions
5 which comprises mixing at least one active agent with at least one compound as described above, and optionally, a dosing vehicle.

In an alternative embodiment, these non-toxic compounds are orally administered to animals as part of a delivery system by blending or mixing the compounds with an active agent prior to administration.

10

DETAILED DESCRIPTION OF THE INVENTION

The specific compounds of the present invention or salts thereof such as, for example, sodium salts, may be used to deliver various active agents through various biological, chemical, and physical barriers. These compounds
15 are particularly suited for delivering active agents which are subject to environmental degradation. The compounds and compositions of the subject invention are particularly useful for delivering or administering biologically-active agents to any animals such as birds; mammals, such as primates and particularly humans; and insects.

20 Other advantages of the present invention include the use of easy to prepare, inexpensive raw materials. The compositions and the formulation methods of the present invention are cost effective, simple to perform, and amenable to industrial scale up for commercial production.

Amino acids, poly amino acids, and peptides, in modified form, may
25 be used to deliver active agents including, but not limited to, biologically active agents such as for example, pharmacological and therapeutic agents.

An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids.


Poly amino acids are either peptides or two or more amino acids
30 linked by a bond formed by other groups which can be linked, e.g. an ester, anhydride, or an anhydride linkage. Special mention is made of non-naturally occurring poly amino acids and particularly non-naturally occurring hetero poly amino acids, i.e. polymers of mixed amino acids.

Peptides are two or more amino acids joined by a peptide bond. Peptides can vary in length from dipeptides with two amino acids to polypeptides with several hundred amino acids. See Chambers Biological Dictionary, editor Peter M. B. Walker, Cambridge, England: Chambers Cambridge, 1989, page 215. Special mention is made of di-peptides, tri-peptides, tetra-peptides, and penta-peptides.

The terms modified amino acids, modified poly amino acids, and modified peptides are meant to include amino acids which have been modified or poly amino acids and peptides in which at least one amino acid has been modified by acylating at least one free amine group with an acylating agent which reacts with at least one of the free amine groups present.

Modified Amino Acids

Several of the compounds of the present invention are broadly represented by one of formula XLVI or XLVII below:



wherein Ar is a substituted or unsubstituted phenyl or naphthyl;

Y is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$ or $-\text{SO}_2-$, R^1 has the formula $-\text{N}(\text{R}^3)-\text{R}^2-\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$, wherein:


R^2 is C_1 to C_{24} alkyl, C_1 to C_{24} alkenyl, phenyl, naphthyl, $(\text{C}_1$ to C_{10} alkyl) phenyl, $(\text{C}_1$ to C_{10} alkenyl) phenyl, $(\text{C}_1$ to C_{10} alkyl) naphthyl, $(\text{C}_1$ to C_{10} alkenyl) naphthyl, phenyl $(\text{C}_1$ to C_{10} alkyl), phenyl $(\text{C}_1$ to C_{10} alkenyl), naphthyl $(\text{C}_1$ to C_{10} alkyl), and naphthyl $(\text{C}_1$ to C_{10} alkenyl);

R^2 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 alkoxy, $-\text{OH}$, $-\text{SH}$ and $-\text{CO}_2\text{R}^4$ or any combination thereof;

R^4 is hydrogen, C_1 to C_4 alkyl or C_1 to C_4 alkenyl;

R^2 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and

R^3 is hydrogen, C_1 to C_4 alkyl or C_1 to C_4 alkenyl; or




- 5
- 10 wherein: R^5 is (i) $\text{C}_3\text{-C}_{10}$ cycloalkyl, optionally substituted with $\text{C}_1\text{-C}_7$ alkyl, $\text{C}_2\text{-C}_7$ alkenyl, $\text{C}_1\text{-C}_7$ alkoxy, hydroxy, phenyl, phenoxy or $-\text{CO}_2\text{R}^6$, wherein R^6 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or $\text{C}_2\text{-C}_4$ alkenyl; or
- (ii) $\text{C}_1\text{-C}_8$ alkyl substituted with $\text{C}_3\text{-C}_{10}$ cycloalkyl; R^6 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or $\text{C}_2\text{-C}_4$ alkenyl;
- 15 R^7 is $\text{C}_1\text{-C}_{24}$ alkyl, $\text{C}_2\text{-C}_{24}$ alkenyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_3\text{-C}_{10}$ cycloalkenyl, phenyl, naphthyl, ($\text{C}_1\text{-C}_{10}$ alkyl) phenyl, ($\text{C}_2\text{-C}_{10}$ alkenyl) phenyl, ($\text{C}_1\text{-C}_{10}$ alkyl) naphthyl, ($\text{C}_2\text{-C}_{10}$ alkenyl) naphthyl, phenyl ($\text{C}_1\text{-C}_{10}$ alkyl), phenyl ($\text{C}_2\text{-C}_{10}$ alkenyl), naphthyl ($\text{C}_1\text{-C}_{10}$ alkyl) or naphthyl ($\text{C}_2\text{-C}_{10}$ alkenyl);
- R^7 being optionally substituted with $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_2\text{-C}_4$ alkenyl, $\text{C}_1\text{-C}_4$ alkoxy, $-\text{OH}$, $-\text{SH}$, $-\text{CO}_2\text{R}^6$, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_3\text{-C}_{10}$ cycloalkenyl, heterocycle
- 20 having 3-10 ring atoms wherein the hetero atom is one or more of N, O, S or any combination thereof, aryl, ($\text{C}_1\text{-C}_{10}$ alk)aryl, ar($\text{C}_1\text{-C}_{10}$ alkyl), or any combination thereof;
- R^7 being optionally interrupted by oxygen, nitrogen, sulfur, or any
- 25 combination thereof; and
- R^6 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or $\text{C}_2\text{-C}_4$ alkenyl.

Special mention is made of compounds I - XLV above.

The modified amino acids of formulae I-XLV may be prepared by reacting single amino acids, mixtures of two or more amino acids, amino acid

30 esters, or amino acid amides, with an amine modifying agent which reacts with free amino moieties present in the amino acids to form amides.

Modified amino acids are typically prepared by modifying the amino acids or an ester thereof. Many of these compounds are prepared by acylation with acylating agents having the formula



XLVIII

- 5 wherein: R^{10} is the appropriate radical to yield the modification indicated in the

final product as would be within the skill of the art based upon the detailed disclosure herein, and Y is a leaving group. Typical leaving groups include, but are not limited to, halogens such as, for example, chlorine, bromine, and iodine.

- 10 Additionally, the corresponding anhydrides are suitable acylating agents.

Many of the compounds of the present invention can be readily prepared and modified by methods within the skill of those in the art based upon the present disclosure. For example, the modified amino acid compounds above may be prepared by reacting the single amino acid with the appropriate acylating agent or an amine modifying agent which reacts with free amino moiety present

15 in the amino acids to form amides. Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art.

- For example, the amino acid can be dissolved in aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide, and heated
- 20 at a temperature ranging between about 5°C and about 70°C, preferably between about 10°C and about 40°C, for a period ranging between about 1 hour and about 4 hours, preferably about 2.5 hours. The amount of alkali employed per equivalent of NH_2 groups in the amino acid generally ranges between about 1.25 and about 3 mmole, preferably between about 1.5 and
- 25 about 2.25 mmole per equivalent of NH_2 . The pH of the solution generally ranges between about 8 and about 13, preferably ranging between about 10 and about 12.

- Thereafter, the appropriate amino modifying agent is added to the amino acid solution while stirring. The temperature of the mixture is maintained
- 30 at a temperature generally ranging between about 5°C and about 70°C, preferably between about 10°C and about 40°C, for a period ranging between about 1 and about 4 hours. The amount of amino modifying agent employed in relation to the quantity of amino acid is based on the moles of total free NH_2 in the amino acid. In general, the amino modifying agent is employed in an amount

ranging between about 0.5 and about 2.5 mole equivalents, preferably between about 0.75 and about 1.25 equivalents, per molar equivalent of total NH_2 group in the amino acid.

The reaction is quenched by adjusting the pH of the mixture with
5 a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between about 2 and about 3. The mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate. The upper layer is discarded, and the modified amino acid is collected from the lower layer by filtration or decantation. The crude modified
10 amino acid is then dissolved in water at a pH ranging between about 9 and about 13, preferably between about 11 and about 13. Insoluble materials are removed by filtration and the filtrate is dried in vacuo. The yield of modified amino acid generally ranges between about 30 and about 60%, and usually about 45%.

15 If desired, amino acid esters, such as, for example methyl or ethyl esters of amino acid compounds, may be used to prepare the modified amino acids of the invention. The amino acid ester, dissolved in a suitable organic solvent such as dimethylformamide or pyridine, is reacted with the appropriate amino modifying agent at a temperature ranging between about 5°C and about
20 70°C, preferably about 25°C, for a period ranging between about 7 and about 24 hours. The amount of amino modifying agent used relative to the amino acid ester is the same as described above for amino acids.

Thereafter, the reaction solvent is removed under negative pressure and the ester functionality is removed by hydrolyzing the modified amino acid
25 ester with a suitable alkaline solution, e.g. 1N sodium hydroxide, at a temperature ranging between about 50°C and about 80°C, preferably about 70°C, for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group. The hydrolysis mixture is then cooled to room temperature and acidified, e.g. aqueous 25%
30 hydrochloric acid solution, to a pH ranging between about 2 and about 2.5. The modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.

The modified amino acid may be purified by recrystallization or by fractionation on solid column supports. Suitable recrystallization solvent systems include acetonitrile, methanol and tetrahydrofuran. Fractionation may be performed on a suitable solid column supports such as alumina, using methanol/n-propanol mixtures as the mobile phase; reverse phase column supports using trifluoroacetic acid/acetonitrile mixtures as the mobile phase; and ion exchange chromatography using water as the mobile phase. When anion exchange chromatography is performed, preferably a subsequent 0-500 mM sodium chloride gradient is employed.

10 Active Agents

Active agents suitable for use in the present invention include biologically active agents, chemically active agents, including, but not limited to, fragrances, as well as other active agents such as, for example, cosmetics.

Biologically active agents include, but are not limited to, pesticides, pharmacological agents, and therapeutic agents. For example, biologically active agents suitable for use in the present invention include, but are not limited to, peptides, and particularly small peptides; hormones, and particularly hormones which by themselves do not or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; or any combination thereof. Further examples include, but are not limited to, human growth hormones; bovine growth hormones; growth releasing hormones; interferons; interleukin-1; insulin; heparin, and particularly low molecular weight heparin; calcitonin; erythropoietin; atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.

30 Delivery Systems

The compositions of the present invention may include one or more active agents.

In one embodiment, compounds I-XLV or poly amino acids or peptides that include at least one of these compounds may be used directly as a drug delivery carrier by simply mixing one or more compound, poly amino acid or peptide with the active ingredient prior to administration.

5 In an alternative embodiment, the compounds, poly amino acids, or peptide may be used to form microspheres containing the active agent. These compounds, poly amino acids, or peptides are particularly useful for the oral administration of certain biologically-active agents, *e.g.*, small peptide hormones, which, by themselves, do not pass or only pass slowly through the
10 gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastrointestinal tract.

If the modified amino acids, poly amino acids, or peptides are to be converted into microspheres, the mixture is optionally heated to a temperature ranging between about 20 and about 50°C, preferably about 40°C, until the
15 modified amino acid(s) dissolve. The final solution contains between from about 1 mg and to about 2000 mg of compound, poly amino acid, or peptide per mL of solution, preferably between about 1 and about 500 mg per mL. The concentration of active agent in the final solution varies and is dependent on the required dosage for treatment. When necessary, the exact concentration can
20 be determined by, for example, reverse phase HPLC analysis.

When the compounds, poly amino acids, or peptides are used to prepare microspheres, another useful procedure is as follows: Compounds, poly amino acids, or peptides are dissolved in deionized water at a concentration ranging between about 75 and about 200 mg/ml, preferably about 100 mg/ml
25 at a temperature between about 25°C and about 60°C, preferably about 40°C. Particulate matter remaining in the solution may be removed by conventional means such as filtration.

Thereafter, the compound, poly amino acid, or peptide solution, maintained at a temperature of about 40°C, is mixed 1:1 (V/V) with an aqueous
30 acid solution (also at about 40°C) having an acid concentration ranging between about 0.05 N and about 2 N, preferably about 1.7 N. The resulting mixture is further incubated at 40°C for a period of time effective for microsphere formation, as observed by light microscopy. In practicing this invention, the

preferred order of addition is to add the compound, poly amino acid, or peptide solution to the aqueous acid solution.

Suitable acids for microsphere formation include any acid which does not

- 5 (a) adversely effect the modified amino acids, poly amino acids, or peptides *e.g.*, initiate or propagate chemical decomposition;
- (b) interfere with microsphere formation;
- (c) interfere with microsphere incorporation of the cargo;
- 10 and
- (d) adversely interact with the cargo.

Preferred acids for use in this aspect include acetic acid, citric acid, hydrochloric acid, phosphoric acid, malic acid and maleic acid.

A microsphere stabilizing additive may be incorporated into the
15 aqueous acid solution or into the compound or cargo solution prior to the microsphere formation process. With some drugs the presence of such additives promotes the stability and/or dispersibility of the microspheres in solution.

The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (w/v), preferably about 0.5 % (w/v).
20 Suitable, but non-limiting, examples of microsphere stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.

Under the above conditions, the compound molecules, poly amino acids, or peptides form hollow or solid matrix type microspheres wherein the
25 cargo is distributed in a carrier matrix or capsule type microspheres encapsulating liquid or solid cargo. If the compound, poly amino acid, or peptide microspheres are formed in the presence of a soluble material, *e.g.*, a pharmaceutical agent in the aforementioned aqueous acid solution, this material will be encapsulated within the microspheres. In this way, one can encapsulate
30 pharmacologically active materials such as peptides, proteins, and polysaccharides as well as charged organic molecules, *e.g.*, antimicrobial agents, which normally have poor bioavailability by the oral route. The amount of pharmaceutical agent which may be incorporated by the microsphere is

dependent on a number of factors which include the concentration of agent in the solution, as well as the affinity of the cargo for the carrier. The compound, poly amino acid, or peptide microspheres do not alter the physiological and biological properties of the active agent. Furthermore, the encapsulation process
5 does not alter the pharmacological properties of the active agent. Any pharmacological agent can be incorporated within the microspheres. The system is particularly advantageous for delivering chemical or biological agents which otherwise would be destroyed or rendered less effective by conditions encountered within the body of the animal to which it is administered, before
10 the microsphere reaches its target zone (*i.e.*, the area in which the contents of the microsphere are to be released) and for delivering pharmacological agents which are poorly absorbed in the gastro-intestinal tract. The target zones can vary depending upon the drug employed.

The particle size of the microsphere plays an important role in
15 determining release of the active agent in the targeted area of the gastro-intestinal tract. The preferred microspheres have diameters between about \leq 0.1 microns and about 10 microns, preferably between about 0.5 microns and about 5 microns. The microspheres are sufficiently small to release effectively the active agent at the targeted area within the gastro-intestinal tract such as,
20 for example, between the stomach and the jejunum. Small microspheres can also be administered parenterally by being suspended in an appropriate carrier fluid (*e.g.*, isotonic saline) and injected directly into the circulatory system, intramuscularly or subcutaneously. The mode of administration selected will vary, of course, depending upon the requirement of the active agent being
25 administered. Large amino acid microspheres (> 50 microns) tend to be less effective as oral delivery systems.

The size of the microspheres formed by contacting compounds, poly amino acids, or peptides with water or an aqueous solution containing active agents can be controlled by manipulating a variety of physical or chemical
30 parameters, such as the pH, osmolarity or ionic strength of the encapsulating solution, size of the ions in solution and by the choice of acid used in the encapsulating process.

The administration mixtures are prepared by mixing an aqueous solution of the carrier with an aqueous solution of the active ingredient, just prior to administration. Alternatively, the carrier and the biologically active ingredient can be admixed during the manufacturing process. The solutions may
5 optionally contain additives such as phosphate buffer salts, citric acid, acetic acid, gelatin and gum acacia.

Stabilizing additives may be incorporated into the carrier solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.

10 The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (W/V), preferably about 0.5 % (W/V). Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.

15 The amount of active agent is an amount effective to accomplish the purpose of the particular active agent. The amount in the composition typically is a pharmacologically or biologically effective amount. However, the amount can be less than a pharmacologically or biologically effective amount when the composition is used in a dosage unit form, such as a capsule, a tablet
20 or a liquid, because the dosage unit form may contain a multiplicity of carrier/biologically active agent compositions or may contain a divided pharmacologically or biologically effective amount. The total effective amounts can then be administered in cumulative units containing, in total, pharmacologically or biologically active amounts of biologically or
25 pharmacologically active agent.

The total amount of active agent, and particularly biologically active agent, to be used can be determined by those skilled in the art. However, it has surprisingly been found that with some biologically active agents, the use of the presently disclosed carriers provides extremely efficient delivery. Therefore,
30 lower amounts of biologically active agent than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and therapeutic effects.


The amount of carrier in the present composition is a delivery effective amount and can be determined for any particular carrier or biologically active agent by methods known to those skilled in the art.

Dosage unit forms can also include any of excipients; diluents; 5 disintegrants; lubricants; plasticizers; colorants; and dosing vehicles, including, but not limited to water, 1,2-propane diol, ethanol, olive oil, or any combination thereof.

Administration of the present compositions or dosage unit forms preferably is oral or by intraduodenal injection.

10 The delivery compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. These compounds have the formulas below:

15




XLIX

20

Actinonin

25




L

30

Derivatives of these compounds are disclosed in U.S. Patent No. 5,206,384.

Actinonin derivatives have the formula:



wherein R^{12} is sulfoxymethyl or carboxyl or a substituted carboxy group selected from carboxamide, hydroxyaminocarbonyl and alkoxycarbonyl groups; and R^{13} is hydroxyl, alkoxy, hydroxyamino or sulfoxyamino group. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.

The compounds and compositions of the subject invention are useful for administering biologically active agents to any animals such as birds; mammals, such as primates and particularly humans; and insects. The system is particularly advantageous for delivering chemically or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the active agent its target zone (i.e. the area in which the active agent of the delivery composition are to be released) and within the body of the animal to which they are administered. Particularly, the compounds and compositions of the present invention are useful in orally administering active agents, especially those which are not ordinarily orally deliverable.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples illustrate the invention without limitation.

Example 1

Compound VI was prepared as follows:

Acetylsalicyloyl chloride (47.00 g, 0.24 mol, 1 equiv.) was added portionwise to a mixture of 4-(4-aminophenyl)butyric acid (50.00g, 0.28 mol, 1.2 equiv.) in aqueous sodium hydroxide (2M, 300 mL). The reaction was stirred at 25 °C for 2 hours, and the resultant solution was acidified with aqueous hydrochloric acid

(1M) to pH 2.1. The resultant precipitate was filtered, and was washed with aqueous hydrochloric acid (1M, 3 x 100 mL) and water to give Compound VI as a pale pink solid (31.89 g, 52%).

Properties are listed below.

- 5 ¹H NMR (300 MHz, DMSO-d₆) δ: 7.74 (1H, dd), 7.38 (2H, d), 7.21 (3H, m), 6.67 (1H, m), 6.57 (1H, m), 2.48 (2H, t), 2.07 (2H, t), 1.71 (2H, m). Anal. Calcd for C₁₇H₁₇NO₄: C, 68.20; H, 5.73; N, 4.70. Found: C, 68.22; H, 5.61; N, 4.66.

- 10 Similar procedures were used to prepare Compounds II, V, X, XIV, XVIII, XXII, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XL, XLI, XLII, and XLV.

Properties are listed below.

- 15 Compound II - ¹H NMR (300MHz, D₂O): δ 7.23(9H, m), 3.62(2H, s), 2.50(2H, t), 2.17(2H, t), 1.73(2H, q)

- Compound V - Anal. Calcd for C₁₇H₁₇NO₅: C, 64.74, H, 5.45, N, 4.44 Found: C, 64.11, H, 5.46, N, 4.21. ¹H NMR (300MHz, D₂O): δ 7.6 (1H,d), 7.35 (2H,d), 7.15 (2H,m), 6.05 (1H,d), 2.5 (2H,m), 2.1 (2H,t), 1.7 (2H,m)
- 20

- Compound X - Anal. Calcd for C₂₃H₂₉NO₃: C, 75.16, H, 7.97, N, 3.79 Found: C, 74.90, H, 8.19, N, 3.38. ¹H NMR (300MHz, CDCl₃): δ 7.35 (2H,d), 7.27 (2H,d), 7.15 (2H,d), 6.95 (2H,d), 3.7 (1H,q), 2.6 (2H,t), 2.5 (2H,d), 2.35 (2H,t), 1.9 (3H,m), 1.6 (3H,d), 0.9 (6H,d)
- 25

- Compound XVIII - ¹H NMR (300MHz, DMSO-d₆): δ 12.1 (1H,s), 10.5 (1H,s), 8.2 (1H,t), 8.0 (2H,m), 7.7 (3H,d), 7.6 (3H,d), 7.2 (2H,t), 3.3 (1H,m), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,t)

30

- Compound XXII - Anal. Calcd for C₂₀H₂₃NO₃: C, 73.82, H, 7.12, N, 4.30 Found: C, 73.53, H, 7.07, N, 4.28. ¹H NMR (300MHz, DMSO-d₆): δ 12.0

(1H,s), 10.0 (1H,s), 7.6 (2H,m), 7.4 (4H,m), 7.2 (1H,d), 7.0 (2H,q), 3.55 (1H,t), 2.5 (4H,m), 2.2 (2H,q), 2.0 (1H,m), 1.7 (3H,m), 0.9 (3H,t)

Compound XXVI - ^1H NMR (300MHz, D_2O): δ 7.21(2H, d), 7.15(2H, d),
5 2.51(2H,t), 2.45(1H, m), 2.10(2H, t), 1.9-1.3(14H, m)

Compound XXV - Anal. Calcd for $\text{C}_{18}\text{H}_{18}\text{NO}_3\text{F}$: C, 68.56, H, 5.75, N, 4.44 Found: C, 68.18, H, 5.63, N, 4.20. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 12.1 (1H,s), 10.1 (1H,s), 7.5 (2H,m), 7.35 (2H,m), 7.1 (4H,m), 3.6 (2H,s), 2.5 (2H,t), 2.2 (2H,t), 1.75
10 (2H,m)

Compound XXVII - ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 9.75 (1H,s), 7.5 (2H,d), 7.1 (2H,d), 2.5 (3H,q), 2.05 (3H,t), 1.6 (10H,m), 1.1 (5H,m), 0.8 (3H,t)

15 Compound XXVIII - ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 9.82(1H, s), 7.49(2H, d), 7.06(2H,d), 2.48(2H, t), 2.32(1H, m), 2.09(2H, t), 1.71(8H, m), 1.29(6H, m)

Compound XXIX - ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 10.0 (1H,s), 7.5 (2H,d), 7.05 (2H,d), 2.5 (3H,m), 2.15 (2H,d), 1.85 (2H,t), 1.65 (8H,m), 1.2 (3H,m), 1.90(2H,q)
20

Compound XXX - ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 9.85 (1H,d), 7.5 (2H,d), 7.05 (2H,d), 2.45 (3H,m), 1.9 (2H,t), 1.7 (6H,m), 1.4 (4H,m), 0.9 (3H,dd)

Compound XXXIII - ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 11.95(1H, s), 2.2(2H, m),
25 1.8(2H, m), 1.4(10, br m), 0.83(3H, d)

Compound XXXIV - Anal. Calcd for $\text{C}_{13}\text{H}_{19}\text{NO}_3$: C 68.96, H 7.26, N5.36, Found: C 68.75, H 7.24, N 5.30. ^1H NMR (300MHz, D_2O): δ 7.71(2H, d), 7.33(2H, d), 2.06(2H, d), 1.52(6H, m), 1.01(3H, m), 0.84(2H, m)

30 Compound XXXV - Anal. Calcd for $\text{C}_{14}\text{H}_{10}\text{NO}_3\text{Cl}$: C, 60.96, H, 3.63, N, 5.08 Found: C, 60.42, H, 3.64, N, 4.94. ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 10.85 (1H,s), 7.95 (2H,d), 7.85 (2H,d), 7.55 (4H,m)

Compound XXXVI - Anal. Calcd for $C_{16}H_{21}NO_3$: C 69.79, H 7.70, N 5.08; Found: C 69.38, H 7.85, N 4.85. 1H NMR (300MHz, DMSO- d_6): δ 10.0(1H, s), 7.45(2H, d), 7.10(2H, d), 3.18(2H, s), 2.15(2H, d), 1.67(6H, br m), 1.17(3H, m), 0.95(2H, m)

- 5 Compound XXXVII - 1H NMR (300MHz, DMSO- d_6): δ 12.25(1H, s), 9.8(1H, s), 7.5(2H, d), 7.15(2H, d), 3.5(2H, s), 2.3(1H, m), 1.8(4H, m), 0.3(6H, m)

- Compound XXXVIII - Anal. Calcd for $C_{17}H_{13}NO_3$: C, 72.58, H, 5.39, N, 4.98 Found: C, 72.34, H, 5.21, N, 4.93. 1H NMR (300MHz, DMSO- d_6): δ 10.2 (1H, s), 7.6
10 (5H, m), 7.4 (3H, q), 7.2 (2H, d), 6.85 (1H, d), 3.5 (2H, s)

Compound XL - 1H NMR (300MHz, DMSO- d_6): δ 8.6 (1H, m), 7.8 (2H, m), 7.25 (5H, m), 7.1 (2H, dd), 4.25 (2H, d), 3.5 (2H, s)

- 15 Compound XLI - Anal. Calcd for $C_{15}H_{13}NO_3 \cdot 0.27 H_2O$: C, 70.57, H, 5.14, N, 5.49 Found: C, 69.24, H, 5.48, N, 5.37. 1H NMR (300MHz, DMSO- d_6): δ 10.25 (1H, s), 8.0 (2H, d), 7.7 (2H, d), 7.55 (3H, m), 7.25 (2H, d), 3.5 (2H, s)

- Compound XLII - 1H NMR (300MHz, DMSO- d_6): δ 11.89(1H, s), 7.58 (1H, s),
20 2.95(2H, t), 2.16(3H, m), 1.73(2H, t), 1.40(14H, m), 1.20(2H, t)

Example 2

Compound IX was prepared as follows:

- A solution of 4-phenylbutyryl chloride (10.20g, 56 mmol) in
25 tetrahydrofuran (30 mL) was added dropwise to a mixture of 4-(4-aminophenyl)butyric acid (10.00g, 56 mmol, 1.0 equiv.), triethylamine (8.50 mL, 62 mmol, 1.1 equiv.) and tetrahydrofuran (100 mL) at 10 °C. The reaction was stirred at 10 °C for 1 hour and 25 °C for 3 hours. The solvent was then evaporated, and the residue was dissolved in ethyl acetate (150 mL). After
30 washing the ethyl acetate layer with aqueous hydrochloric acid (1M, 3 x 100 mL) and water (2 x 100 mL), the organic layer was dried and evaporated. The resultant residue was recrystallized from acetonitrile-water to give IX as a pale yellow solid (11.69g, 65 %).

Properties are listed below.

^1H NMR (300MHz, alkaline D_2O) δ : 7.05 (2H, m), 6.94 (4H, m), 6.85 (3H, m), 2.30 (4H, m) 2.01 (4H, m), 1.61 (4H, m). Anal. Calcd for $\text{C}_{20}\text{H}_{23}\text{NO}_3$: C, 73.81; H, 7.13; N, 4.30. Found: C, 73.53; H, 7.13; N, 4.25.

5

Similar procedures were used to prepare compounds XV, XVII, XX, and XXI.

Properties are listed below.

10 Compound I - ^1H NMR (300MHz, D_2O): δ 7.75 (2H,q), 7.55 (1H,m), 7.45 (2H,m), 7.35 (2H,dd), 7.2 (2H,dd), 2.55 (2H,m), 2.1 (2H,t), 1.75 (2H,m)

Compound III - Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_3\text{Cl}$: C, 64.26, H, 5.07, N, 4.41 Found: C, 63.29, H, 5.12, N, 4.19. ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 12.1 (1H,s), 10.4 (1H,s), 7.7 (2H,d), 7.6 (2H,d), 7.45 (2H,m), 7.2 (2H,q), 2.6 (2H,m), 2.2 (2H,m), 1.8 (2H,m)

Compound IV - Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_3\text{F}$: C, 67.76, H, 5.35, N, 4.65 Found: C, 67.15, H, 5.33, N, 4.46. ^1H NMR (300MHz, $\text{DMSO}-d_6$): δ 12.05 (1H,s), 10.35 (1H,s), 7.6 (4H,m), 7.3 (2H,q), 7.15 (2H,q), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,m)

Compound VII - ^1H NMR (300MHz, D_2O): δ 7.12(3H, m), 6.88(2H, s), 6.67(5H, br m), 6.26(1H, d), 2.18(2H, t), 1.96(2H, t), 1.50(2H, q)

25

Compound VIII - ^1H NMR (300MHz, D_2O): δ 6.9 (9H,m), 2.6 (2H,t), 2.3 (4H,t), 2.0 (2H,q), 1.6 (2H,m)

Example 3

30 Compound XXIV was prepared as follows:

N-hydroxysuccinamide (8.86 g, 77.00 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (15.88 g, 77.00 mmol, 1.1 equiv.) were added to a solution of 3-(4-fluorobenzoyl)propionic acid (13.73 g, 70.00 mmol, 1 equiv.)

in dimethylformamide (250 mL). The reaction was stirred at 25°C under nitrogen for 12 hours. The solution was diluted with water (500 mL) and extracted with chloroform (250 mL). The organic layer was dried and filtered. Glacial acetic acid (5 mL) was added to the filtrate, and this mixture stirred for 1 hour. The resulting chloroform solution was washed with sodium bicarbonate (250 mL) and water (250 mL) and dried over magnesium sulfate. After filtration, 4-(4-aminophenyl)butyric acid (12.5 g, 70.00 mmol, 1 equiv.) and triethylamine (16 mL) were added to the filtrate. The resulting mixture was stirred at 25°C overnight, and it was then acidified with hydrochloric acid (250 mL) and lyophilized to yield XXIV as a white solid. (3.50 g, 14%).

Properties are listed below.

¹H NMR (300MHz, DMSO-d₆) δ: 12.05 (H, br s), 9.95 (1H, s), 8.10 (2H, t), 7.50 (2H, d), 7.35 (2H, t), 7.10 (1H, d), 2.70 (2H, t), 2.20 (2H, t), 1.75 (2H, m). Anal. Calcd for C₂₀H₂₀NO₄F: C, 67.02; H, 5.62; N, 3.90. Found: C, 67.08; H, 5.60; N, 3.86.

Similar procedures were used to prepare compound XLIII and XLIV.

Properties are listed below.

Compound XLIII - Anal. Calcd for C₂₂H₂₇NO₃ · 0.083 H₂O: C, 74.44, H, 7.73, N, 3.95 Found: C, 73.96, H, 7.73, N, 4.26. ¹H NMR (300MHz, DMSO-d₆): δ 12.71 (1H,s), 8.2 (1H,q), 7.1 (9H,m), 4.4 (1H,m), 3.6 (1H,m), 3.0 (1H,m), 2.85 (1H,m), 2.4 (1H,q), 1.8 (1H,m), 1.3 (2H,d), 1.15 (1H,d), 0.85 (6H,d)

Compound XLIV - Anal. Calcd for C₂₂H₁₇NO₄F₂: C, 66.49, H, 4.32, N, 3.53 Found: C, 66.14, H, 4.29, N, 3.33. ¹H NMR (300MHz, DMSO-d₆): δ 8.05 (1H,s), 7.5(2H,m), 7.35 (1H,m), 7.2(7H,m), 7.0 (1H,d), 4.7 (1H,m), 3.2 (1H, dd), 3.05 (1H, m)

Example 4

Compound XXXII was prepared as follows:

1-oxaspiro(2.5)octane (3.76 g, 33.48 mmol, 1.2 equiv.) and aluminum chloride (0.36 g, 2.70 mmol, 0.1 equiv.) were added to a suspension

of 4-(4-aminophenyl)butyric acid (5.00 g, 27.90 mmol, 1 equiv.) in toluene (100 mL). The mixture was refluxed under argon overnight. After being cooled to room temperature, the toluene was filtered, and the residue was washed with ethyl acetate (ca. 100 mL). The combined filtrate was evaporated to yield a brown gum. The gum was dissolved with ethyl acetate (250 mL). It was then washed with water (3 x 100 mL) and dried. After removal of the solvent, the residue was purified by column chromatography (30 % to 70 % ethyl acetate/hexanes), and the collected product was recrystallized from ethyl acetate-hexanes to give XXXII as yellow solid (0.8 g, 10 %).

Properties are listed below.

^1H NMR (300 MHz, DMSO- d_6) δ : 6.85 (2H, d, J = 8.4 Hz), 6.53 (2H, d, J = 8.4 Hz), 5.00 (1H, br s), 2.88 (2H, s), 2.39 (2H, t, J = 7.2 Hz), 2.15 (2H, t, J = 7.4 Hz), 1.69 (2H, m), 1.45 (10H, m). Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3$: C, 70.07; H, 8.65; N, 4.81.

Found: C, 70.20; H, 8.69; N, 4.67.

Example 5

Compound XXXIX was prepared as follows:

N-hydroxysuccinimide (7.72 g, 67.50 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (13.96 g, 67.50 mmol, 1.1 equiv.) were added to a solution of N-(2-phenylbutyryl)-4-(aminophenyl)butyric acid (20.00 g, 61.40 mmol, 1.0 equiv.) in tetrahydrofuran (400 mL). The reaction was stirred overnight at 25°C. The urea formed was removed by filtration. Glacial acetic acid (5 mL) was added to the filtrate and stirred for 2 hours. The solvent was then evaporated to yield an oil. The oil was redissolved in chloroform (300 mL), and the resultant solution was washed successively with saturated sodium bicarbonate (2 x 200 mL) and water (200 mL). The combined aqueous layers were extracted with chloroform (100 mL) to give a filtrate (a total volume of 500 mL) containing the Osu ester of N-(2-phenylbutyryl)-4-(4-aminophenyl)butyric acid.

A mixture of phenylglycine O-methylester hydrochloride (12.40 g, 61.40 mmol, 1.0 equiv.) and triethylamine (35 mL) in chloroform (100 mL) was charged to an addition funnel. The mixture was added dropwise to the

chloroform solution of the Osu ester prepared above. The reaction was stirred at 25°C for 24 h. The resulting solution was washed with aqueous hydrochloric acid (2 x 500 mL) and water (500 mL). The aqueous layer was back extracted with chloroform (50 mL). The combined chloroform layers were dried and
5 evaporated to yield an oil. Aqueous sodium hydroxide (2M, 200mL) was added to the oil, and the mixture was heated to 100°C for 2 h. After being cooled to room temperature, the solution was acidified with hydrochloric acid (2 M) to pH 2.5. The precipitate was filtered, washed with hydrochloric acid (100 mL) and water (100mL) to give XXXIX as an off white solid (15.2 g, 54%).

10 Properties are listed below.

¹H NMR (300MHz, DMSO-d₆) δ: 12.70 (1H, br s), 10.00 (1H, s), 8.55 (1H, d), 7.50 (2H, d), 7.33 (10H, m), 7.06 (2H, d), 5.32 (1H, d), 3.54 (1H, m), 2.49 (2H, overlapped with DMSO), 2.16 (2H, m), 2.05 (1H, m), 1.73 (3H, m), 0.83 (3H, t). Anal. Calcd for
15 C₂₈H₃₀N₂O₄: C, 73.30; H, 6.61; N, 5.73; Found: C, 72.54; H, 6.60; N, 5.73.

Example 6 - In Vivo Evaluation of Interferon in Rats

Dosing compositions were prepared by mixing the modified amino
20 acid compounds and interferon α2 as listed in Table 1 below in a Trizma® hydrochloride buffer solution (Tris-HCl) at a pH of about 7-8. Propylene glycol (0-25%) was added as a solubilizing agent, if necessary.

Rats were orally or intraduodenally (ID) administered the dosing compositions, and delivery was evaluated by an ELISA assay for human
25 interferon α-2b.

Results are illustrated in Table 1 below.

TABLE - 1			
Oral Delivery of Interferon			
Carrier	Carrier Dose (mg/kg)	Interferon Dose (μ g/kg)	Mean Peak Serum Levels of Interferon (ng/mL)
XXVI	300	1000	6710 +/- 6658
XXXVII	160	1000	1025 +/- 276
XXVII	300	1000	3642 +/- 5895
XXXIV	400	1000	11341 +/- 8793
	400	500	565 +/- 515
XXXIV (ID)	400	100	1775 +/- 1023
XXIX	600	100	3510 +/- 2171
I	300	1000	10072 +/- 3790
I (ID)	250	50	843 +/- 669
I	80	250	1369 +/- 1164
VI	300	1000	8213 +/- 3077
VI	600	1000	8428 +/- 5001
VI (ID)		1000	15469 +/- 6712
XXXVI	400	1000	43961 +/- 14910
XIV	800	1000	5518 +/- 2718
VII	600	1000	5568 +/- 3771
XXVII	300	1000	41966 +/- 19688
VIII	300	1000	1753 +/- 1529
XVIII	300	1000	19809 +/- 26107
XXX	300	1000	3910 +/- 3221
XL	300	1000	12661 +/- 10933
none	0	1000	688 +/- 173

Example 7 - *In Vivo* Evaluation of Salmon Calcitonin in Rats

Dosing compositions were prepared and dosed using the modified amino acid compound carriers and salmon calcitonin as listed in Table 2 below.

The concentration of calcitonin in each composition was 2.5 μ g/ml. Each rat was administered 2 ml/kg of dosing composition.

Blood samples were collected serially from the tail artery. Serum calcium was determined by testing with a Calcium Keto (Sigma Chemical Co. - St. Louis, MO.)

Results are illustrated in Table 2 below.

5

Example 8 - *In Vivo* Evaluation of Salmon Concentration in Rats

A dosing composition was prepared using 400 mg of compound VI with 2.9 ml of 25% aqueous propylene glycol. The resultant solution was stirred, and the pH was adjusted to 7.2 with sodium hydrochloride (1.010).

10 Water was added to bring the total volume to 2.0 ml and a final modified amino acid concentration of 200 mg/ml. Salmon calcitonin (10 mg) was added.

This composition was dosed as described in Example 7 above.

Results are illustrated in Table 2 below.

15

TABLE - 2			
Oral Delivery of Calcitonin			
Carrier	Carrier Dose (mg/kg)	Dose Drug (μ g/kg)	Mean Peak Serum Levels of Interferon (ng/mL)
XXVI	10	300	-18 +/- 6
20 XXVIII	10	200	-14 +/- 6
I	10	200	-16 +/- 8
VII	10	200	-13 +/- 8
VI	10	200	-29 +/- 14
	30	10	-13 +/- 4
	10	30	-24 +/- 9

25

Example 9 - *In Vivo* Evaluation of Recombinant Human Growth Hormone (rhGh) in Rats

Dosing compositions were prepared with modified amino acids in
30 a phosphate buffer at a pH of about 7-8 and rhGH as listed in Table 3 below.

Rats were administered the compositions by oral gavage, intraduodenal administration (ID), or colonic administration (IC).

Results are illustrated in Table 3 below.

	TABLE - 3			
	Oral Delivery of rhGH			
	Carrier	Carrier Dose (mg/mL)	Dose Drug (mg/mL)	Mean Peak Serum Levels of rhGH (ng/mL)
5	XXVI	500	6	-127 +/- 40
	XXVII	500	6	-64 +/- 7
10	VI	150	6	-33 +/- 13
	VI (ID)	200	3	-103 +/- 85
	VI (IC)	50	1.5	-98 +/- 19
	II	400	6	55 +/- 36
	XXX	400	6	66 +/- 37
15	XLV	400	6	28 +/- 9
	IV	300	6	42 +/- 29
	XLIII	300	6	63 +/- 45
	X	250	6	37 +/- 12
	XXXII	200	6	44 +/- 36
20	none	0	6	<10

Example 10 - In Vivo Evaluation of Heparin in Rats

900 mg of modified amino acid were dissolved in 3 ml of propylene glycol, and 0.299 gram of sodium heparin was dissolved in 3 ml of water. The two solutions were mixed by vortex. Sodium hydrochloride was added to the resultant mixture until a solution was obtained. The pH was then adjusted to 7.4 ± 0.5 with concentrated hydrochloric acid. The final solution was sonicated at 40 °C for 30 minutes to yield a dosing solution.

The dosing solution was administered by oral gavage to fasted rats.

Blood samples were collected by cardiac puncture following the administration of ketamine (44 mg/kg). Heparin activity was determined by

utilizing the activated partial thromboplastin time (APTT) according to the method of Henry, J. B., *Clinical Diagnosis and Management by Laboratory Methods*; Philadelphia, PA; WB Saunders (1979). Results are illustrated in Table 4 below.

5	TABLE - 4		
	Oral Delivery of Heparin		
	Carrier	Mean Peat APTT (sec)	# Animals Responding
	XXI	166 +/- 35	5/5
	IX	102 +/- 33	34/35
10	VI	96 +/- 29	10/10
	XLI	90 +/- 49	5/5
	XXXV	73 +/- 16	4/4
	VII	52 +/- 24	17/20
	E-466	67 +/- 30	4/5
15	XX	59 +/- 42	4/4
	VII	58 +/- 28	14/15
	XLII	45 +/- 14	5/5
	XXXIII	44 +/- 28	12/20
	XXVII	44 +/- 15	18/20
20	V	42 +/- 16	4/5
	III	41 +/- 18	8/10
	II	41 +/- 24	3/5
	XXXIX	40 +/- 17	5/10
	XIX	37 +/- 11	4/5
25	XXII	36 +/- 19	6/11
	XXVIII	35 +/- 9	3/5
	none	20.7 +/- 0.17	100/100

Example 11







30 Low molecular weight heparin was dosed according to the method of Example 10.

The above mentioned patents, applications, test methods, and publications are hereby incorporated by reference in their entirety.

Many variations of the present invention will suggest themselves
5 to those skilled in the art in light of the above detailed description. All such obvious variations are within the full intended scope of the appended claims.


WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of




36

8




VII

9




VIII

10




IX

11




X

12



XI


13



XII


37

14




XIII

15




XIV

16




XV

17




XVI

18



XVII


19



XVIII


38

20




XIX

21




XX

22




XXI

23




XXII

24




XXIII

25




XXIV

26




XXV

27




XXVI

28




XXVII

29




XXVIII

30



XXIX


31



XXX


40

32




XXXI

33




XXXII

34




XXXIII

35




XXXIV

36



XXXV


37



XXXVI


41

38




XXXVII

39




XXXVIII

40




XXXIX

41



XL


42



XLI


42

43




XLII

44




XLIII

45



XLIV

46




XLV

47

or salts thereof.


- 1 2. A poly amino acid comprising at least one compound
2 selected from the group consisting of

3




I

4




II

5




III

6




IV

7




V

8




VI

9




VII

10




VIII

11




IX

12




X

13



XI


14



XII


45

15




XIII

16




XIV

17




XV

18




XVI

19



XVII


20



XVIII


46

21




XIX

22




XX

23




XXI

24




XXII

25



XXIII


26



XXIV


47

27




XXV

28




XXVI

29




XXVII

30



XXVIII


31



XXIX


48

32




XXX

33




XXXI

34




XXXII

35




XXXIII

36




XXXIV

37




XXXV

38




XXXVI

39




XXXVII

40




XXXVIII

41



XXXIX


42



XL


50

43




XLI

44




XLII

45




XLIII

46



XLIV

47



XLV

48

or salts thereof.

1 3. A poly amino acid as defined in claim 2, comprising a
2 peptide.

1 4. A composition comprising
2 a. an active agent; and
3 b. a compound as defined in claim 1.

1 5. A composition comprising
2 a. an active agent; and
3 b. a poly amino acid as defined in claim 2.

1 6. A composition as defined in claim 5, wherein said poly amino
2 acid comprises a peptide.

1 7. A composition as defined in claim 4, wherein said active
2 agent comprises a biologically active agent.

1 8. A composition as defined in claim 7, wherein said biologi-
2 cally-active agent is selected from the group consisting of a peptide, a
3 mucopolysaccharide, a carbohydrate, a lipid, a pesticide, or any combination
4 thereof.

1 9. A composition as defined in claim 8, wherein said biologi-
2 cally-active agent is selected from the group consisting of human growth
3 hormone, bovine growth hormone, growth hormone-releasing hormone, an
4 interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial
5 naturetic factor, an antigen, a monoclonal antibody, somatostatin,
6 adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin,
7 cromolyn sodium, vancomycin, desferrioxamine (DFO), or any combination
8 thereof.

1 10. A composition as defined in claim 5, wherein said active
2 agent comprises a biologically active agent.

1 11. A composition as defined in claim 10, wherein said biologi-
2 cally-active agent is selected from the group consisting of a peptide, a
3 mucopolysaccharide, a carbohydrate, a lipid, a pesticide, or any combination
4 thereof.

1 12. A composition as defined in claim 11, wherein said biologi-
2 cally-active agent is selected from the group consisting of human growth
3 hormone, bovine growth hormone, growth hormone-releasing hormone, an
4 interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial
5 nuretic factor, an antigen, a monoclonal antibody, somatostatin,
6 adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin,
7 cromolyn sodium, vancomycin, desferrioxamine (DFO), or any combination
8 thereof.

1 13. A composition as defined in claim 6, wherein said active
2 agent comprises a biologically active agent.

1 14. A composition as defined in claim 13, wherein said biologi-
2 cally-active agent is selected from the group consisting of a peptide, a
3 mucopolysaccharide, a carbohydrate, a lipid, a pesticide, or any combination
4 thereof.

1 15. A composition as defined in claim 14, wherein said biologi-
2 cally-active agent is selected from the group consisting of human growth
3 hormone, bovine growth hormone, growth hormone-releasing hormone, an
4 interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial
5 nuretic factor, an antigen, a monoclonal antibody, somatostatin,
6 adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin,
7 cromolyn sodium, vancomycin, desferrioxamine (DFO), or any combination
8 thereof.

1 16. A dosage unit form comprising
2 (A) a composition according to claim 4; and

- 3 (B) (a) an excipient,
4 (b) a diluent,
5 (c) a disintegrant,
6 (d) a lubricant,
7 (e) a plasticizer,
8 (f) a colorant,
9 (g) a dosing vehicle, or
10 (h) any combination thereof.

1 17. A dosage unit form according to claim 16, comprising a
2 tablet, a capsule, or a liquid.

- 1 18. A dosage unit form comprising
2 (A) a composition according to claim 5; and
3 (B) (a) an excipient,
4 (b) a diluent,
5 (c) a disintegrant,
6 (d) a lubricant,
7 (e) a plasticizer,
8 (f) a colorant,
9 (g) a dosing vehicle, or
10 (h) any combination thereof.

1 19. A dosage unit form according to claim 18, comprising a
2 tablet, a capsule, or a liquid.

- 1 20. A dosage unit form comprising
2 (A) a composition according to claim 6; and
3 (B) (a) an excipient,
4 (b) a diluent,
5 (c) a disintegrant,
6 (d) a lubricant,
7 (e) a plasticizer,
8 (f) a colorant,

- 9 (g) a dosing vehicle, or
10 (h) any combination thereof.

1 21. A dosage unit form according to claim 20, comprising a
2 tablet, a capsule, or a liquid.

1 22. A method for administering a biologically-active agent to an
2 animal in need of said agent, said method comprising administering orally to said
3 animal a composition as defined in claim 4.

1 23. A method for administering a biologically-active agent to an
2 animal in need of said agent, said method comprising administering orally to said
3 animal a composition as defined in claim 5.

1 24. A method for administering a biologically-active agent to an
2 animal in need of said agent, said method comprising administering orally to said
3 animal a composition as defined in claim 6.

1 25. A method for preparing a composition, said method
2 comprising mixing:
3 (A) at least one biologically-active agent;
4 (B) at least one compound as defined in claim 1; and
5 (C) optionally a dosing vehicle

1 26. A method for preparing a composition, said method
2 comprising mixing:
3 (A) at least one biologically-active agent;
4 (B) at least one poly amino acid as defined in claim 2; and
5 (C) optionally a dosing vehicle

1 27. A method for preparing a composition, said method
2 comprising mixing:
3 (A) at least one biologically-active agent;

- 4 (B) at least one peptide as defined in claim 3; and
- 5 (C) optionally a dosing vehicle.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/13527

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/16; 9/50

US CL :424/490

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/490, 488, 487, 451 and 433

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,873,087 (MORISHITA ET AL) 10 October 1989, See entire document.	1-15, 22-24
Y	US, A, 5,122,367 (RON) 16 June 1992, See entire document.	1-27

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 JANUARY 1996

Date of mailing of the international search report

07 FEB 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM E. BENSTON, JR.

Telephone No. (703) 308-2351

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.